Plain-English translation of NCT05377047 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This international trial is testing whether combining stereotactic ablative radiotherapy (a precise, focused radiation treatment) with standard first-line systemic therapy can help patients with oligometastatic breast cancer — cancer that has spread to only a few spots in one or two parts of the body. Half of participants will receive the standard treatment alone, while the other half will receive standard treatment plus the radiation therapy. The main goal is to see if adding this radiation treatment helps people stay cancer-free longer.
When breast cancer spreads to only a few locations, doctors wonder whether aggressively treating those specific spots with radiation — in addition to systemic therapy — might help patients live longer and delay further disease progression. This trial will provide evidence to answer that question.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either receive standard first-line systemic therapy alone or to receive that same therapy plus stereotactic ablative radiotherapy (a focused radiation treatment delivered to your metastatic spots). If you are in the radiation group, you will undergo imaging and planning, followed by several radiation sessions — the exact number and timing depend on where your metastases are located. Throughout the trial, you will have regular hospital visits for imaging, blood tests, and check-ups to monitor how well the treatment is working, any side effects you experience, and your quality of life.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Sweden
Sponsor
Vastra Gotaland Region
Collaborators
Sahlgrenska University Hospital, Azienda Ospedaliero-Universitaria Careggi
Enrollment target
~345 participants
Started
September 2022
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2022.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Katarzyna Kulbacka-Ortiz, CTO
Sahlgrenska University Hospital, Gothenburg
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.